

Ministry of Health

Health Programs and Delivery Division

Drug Submission Status

Report for November 2025

Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via an HPDD Notice.

| Manufacturer | Product | Reference Product | Generic Name | Strength | Dosage Form | DIN |
|-------------------------|---------------------------------|-------------------|-------------------|----------|-------------------------|----------|
| Mantra Pharma Inc. | M-Metformin | Glucophage | METFORMIN HCL | 1000 mg | tablet | 02548275 |
| Juno Pharma Canada Inc. | Micafungin Sodium for Injection | Mycamine | MICAFUNGIN SODIUM | 50 mg | powder for solution, IV | 02547228 |
| Juno Pharma Canada Inc. | Micafungin Sodium for Injection | Mycamine | MICAFUNGIN SODIUM | 100 mg | powder for solution, IV | 02547236 |
| Laboratoire Riva Inc. | Riva-Rupatadine | Rupall | RUPATADINE | 10 mg | tablet | 02560119 |